Evidence map›Paper›PMID 34063043›Full record

ReviewMolecules (Basel, Switzerland)2021

Functional Pyrazolo[1,5-

Andres Arias-Gómez, Andrés Godoy, Jaime Portilla

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Article
  3. Access to Pyrazolo[1,5-Organic letters · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Advances in pyrazolo[1,5-RSC advances · 2025
    Review
  9. An Efficient Synthesis of 3,5-Bis-Aminated Pyrazolo[1,5-Molecules (Basel, Switzerland) · 2025
    Article
  10. Review
  11. Review
  12. Regioselective C(spRSC advances · 2024
    Article
  13. Synthesis of triazole bridgedRSC advances · 2024
    Article
  14. Article
  15. Article
  16. KACS omega · 2023
    Article
  17. Article
  18. D-π-A-Type Pyrazolo[1,5-Materials (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Amphipolar, Amphiphilic 2,4-diarylpyrano[2,3-Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andres Arias-GómezBioorganic Compounds Research Group, Department of Chemistry, Universidad de los Andes, Carrera 1 No. 18A-10, Bogotá 111711, Colombia.ORCID 0000-0002-2196-2204
Andrés GodoyBioorganic Compounds Research Group, Department of Chemistry, Universidad de los Andes, Carrera 1 No. 18A-10, Bogotá 111711, Colombia.
Jaime PortillaBioorganic Compounds Research Group, Department of Chemistry, Universidad de los Andes, Carrera 1 No. 18A-10, Bogotá 111711, Colombia.ORCID 0000-0002-8206-7481
Universidad de Los Andes · CO

Funding

Facultad de Ciencias, Universidad de los Andes, Bogotá - Colombia INV-2019-84-1800 and INV-2020-104-2035
6 · The paper itself

Abstract

Pyrazolo[1,5-

Indexed as

AnimalsAntineoplastic AgentsCatalysisEnzyme InhibitorsHumansPyrazolesPyrimidinesAntineoplastic AgentsEnzyme InhibitorsPyrazolesPyrimidinesantitumor scaffoldenzymatic inhibitoryfunctionalizationN-heterocyclic compoundsorganic synthesispyrazolo[1,5-a]pyrimidine

Identifiers

PMID34063043
PMCPMC8125733
OpenAlexW3160832162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.